

HOUSE COMMITTEE OF REFERENCE AMENDMENT
Committee on Health & Insurance.

SB21-175 be amended as follows:

1 Amend reengrossed bill, page 18, line 3, strike "AN INITIAL" and
2 substitute "A".

3 Page 18, line 11, strike "AN INITIAL" and substitute "A".

4 Page 19, after line 1 insert:

5 "(2) NOTWITHSTANDING ANY PROVISION OF THIS PART 13 TO THE
6 CONTRARY, A BRAND-NAME DRUG, BIOLOGICAL PRODUCT, OR BIOSIMILAR
7 PRODUCT IS NOT SUBJECT TO AN AFFORDABILITY REVIEW BY THE BOARD
8 WITHIN THE FIRST FIVE YEARS OF THE BRAND-NAME DRUG'S, BIOLOGICAL
9 PRODUCT'S, OR BIOSIMILAR PRODUCT'S COMMERCIAL AVAILABILITY.".

10 Renumber succeeding subsections accordingly.

11 Page 22, line 11, strike "10-16-1306 (7)(b)" and substitute "10-16-1306
12 (8)(b)".

13 Page 33, line 17, strike "10-16-1306 (4)" and substitute "10-16-1306 (5)"
14 and strike "10-16-1306 (6); and substitute "10-16-1306 (7);".

*** * * * *